Table 3 |
||
|
Skeletal-related events in patients developing bone metastases during the five year study period |
||
| Clodronate |
Placebo |
|
|
|
||
| Total number of patients |
530 |
539 |
| Skeletal-related event |
||
| Confirmed bone metastases |
51 (9.6%) % of bone |
73 (13.5%) % of bone |
| Radiation therapy |
24 (4.5%) (48%) |
47 (8.7%) (69%) |
| Non-vertebral fracture |
6 (1.1%) (2%) |
16 (2.9%) (22%) |
| Vertebral fracture |
6 (1.1%) (2%) |
14 (2.6%) (19%) |
| Hypercalcemia |
3 (0.5%) (1%) |
11 (2.0%) (15%) |
| Spinal cord compression |
2 (0.4%) (1%) |
5 (0.9%) (7%) |
| Bone surgery |
1 (0.2%) (1%) |
4 (0.7%) (5%) |
| Overall for 5 year study period1 (any skeletal event) |
29 (5.5%) (0.4%) |
53 (9.8%) (73%) |
|
|
||
|
1P < 0.01 versus placebo. |
||
|
Powles et al. Breast Cancer Research 2006 8:R13 doi:10.1186/bcr1384 |
||
